PURPOSE OF REVIEW: The only currently approved treatment for primary sclerosing cholangitis (PSC) is liver transplantation, with a median time to transplant of 12-18 years after diagnosis. There are a number of emerging drugs that have the potential to meet this critically unmet need that will be summarized and discussed herein. RECENT FINDINGS: Although the cause of PSC is unknown, there are a number of novel therapeutics under development. These drugs target presumed pathogenic mechanisms largely extrapolated from ex-vivo and in-vivo preclinical models, as well as translational observations. SUMMARY: Future therapeutic strategies for PSC may include a multitude of complex pathogenic mechanisms encompassing pathways of immunomodulation, the microbiome and inflammation-related fibrosis.
PURPOSE OF REVIEW: The only currently approved treatment for primary sclerosing cholangitis (PSC) is liver transplantation, with a median time to transplant of 12-18 years after diagnosis. There are a number of emerging drugs that have the potential to meet this critically unmet need that will be summarized and discussed herein. RECENT FINDINGS: Although the cause of PSC is unknown, there are a number of novel therapeutics under development. These drugs target presumed pathogenic mechanisms largely extrapolated from ex-vivo and in-vivo preclinical models, as well as translational observations. SUMMARY: Future therapeutic strategies for PSC may include a multitude of complex pathogenic mechanisms encompassing pathways of immunomodulation, the microbiome and inflammation-related fibrosis.
Authors: Alexander G Miethke; Wujuan Zhang; Julia Simmons; Amy E Taylor; Tiffany Shi; Shiva Kumar Shanmukhappa; Rebekah Karns; Shana White; Anil G Jegga; Celine S Lages; Stephenson Nkinin; Bradley T Keller; Kenneth D R Setchell Journal: Hepatology Date: 2015-08-21 Impact factor: 17.425
Authors: Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner Journal: J Hepatol Date: 2014-02-19 Impact factor: 25.083
Authors: Cyriel Y Ponsioen; Roger W Chapman; Olivier Chazouillères; Gideon M Hirschfield; Tom H Karlsen; Ansgar W Lohse; Massimo Pinzani; Erik Schrumpf; Michael Trauner; Gregory J Gores Journal: Hepatology Date: 2015-12-23 Impact factor: 17.425
Authors: Omar Y Mousa; Brian D Juran; Bryan M McCauley; Mette N Vesterhus; Trine Folseraas; Coleman T Turgeon; Ahmad H Ali; Erik M Schlicht; Elizabeth J Atkinson; Chang Hu; Denise Harnois; Elizabeth J Carey; Andrea A Gossard; Devin Oglesbee; John E Eaton; Nicholas F LaRusso; Gregory J Gores; Tom H Karlsen; Konstantinos N Lazaridis Journal: Hepatology Date: 2021-06-15 Impact factor: 17.425